GoodRx partnered with Novo Nordisk to offer Ozempic and Wegovy pens for $499/month to self-paying patients, expanding access for those without adequate insurance. This makes them available at over 70,000 U.S. pharmacies. Hims & Hers down.
Novo Nordisk's Wegovy (semaglutide) is now FDA-approved for metabolic dysfunction-associated steatohepatitis (MASH) with liver scarring, a significant advancement for this serious condition.
Lilly's new oral GLP-1, orforglipron, shows 11-12.4% weight loss in late-stage trial, short of Zepbound and Wegovy. Easier to produce and distribute than injectables, it targets wider patient access. FDA submission this year.
Novo Nordisk faces slowing growth, fierce competition from Eli Lilly and copycats in the US, prompting a CEO change and strategic refocus.
The Trump administration is considering a five-year pilot program for Medicare & Medicaid to cover costly GLP-1 weight-loss drugs like Wegovy & Zepbound for millions, a significant policy shift.
Novo Nordisk cut its 2025 sales and profit forecast due to slower US Wegovy & Ozempic sales, hit by competition and compounded GLP-1s. Maziar Mike Doustdar is the new CEO.
